Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 14/20 | 0.72 |
| ▸ | CTSG | P08311 | 13/20 | 0.72 |
| ▸ | KLK14 | Q9P0G3 | 13/20 | 0.72 |
| ▸ | KLK5 | Q9Y337 | 13/20 | 0.72 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.72 |
| ▸ | CTRC | Q99895 | 4/20 | 0.66 |
| ▸ | C1R | P00736 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23159974 | 1.00 | KLK7 (0.72) | KLK7CTSGKLK14KLK5PRSS1 | |
| SCHEMBL23160011 | 0.92 | KLK7 (0.72) | KLK7CTSGKLK14KLK5PRSS1 | |
| SCHEMBL23159919 | 0.91 | KLK7 (0.70) | KLK7CTSGKLK14KLK5PRSS1 | |
| SCHEMBL29838634 | 0.91 | KLK7 (0.70) | KLK7CTSGKLK14KLK5PRSS1 | |
| SCHEMBL23159921 | 0.85 | KLK7 (0.74) | KLK7CTSGKLK14KLK5PRSS1 | |
| SCHEMBL29838660 | 0.85 | KLK7 (0.74) | KLK7CTSGKLK14KLK5PRSS1 | |
| SCHEMBL26480280 | 0.85 | KLK7 (0.57) | KLK7CTSGKLK14KLK5PRSS1 | |
| SCHEMBL18352896 | 0.84 | KLK7 (1.00) | KLK7CTSGKLK14KLK5PRSS1 | |
| SCHEMBL26480185 | 0.83 | KLK7 (0.72) | KLK7CTSGKLK14KLK5PRSS1 | |
| SCHEMBL26480336 | 0.83 | KLK7 (0.57) | KLK7CTSGKLK14KLK5PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4037687-B1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | MOLECULAR SKIN THERAPEUTICS INC (US) | 2025-10-29 | — | — | EP | disclosed |
| CN-114615984-B | Benzoxazinone compounds as dual KLK5/7 inhibitors | 分子皮肤治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| US-11643420-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | MOLECULAR SKIN THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-4037687-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | Molecular Skin Therapeutics, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643420-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | KLK5, KLK1, KLK2 | KLK7 4/4885CTSG 290/4885KLK14 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.